Skip to main content
Nuclear Medicine and Molecular Imaging logoLink to Nuclear Medicine and Molecular Imaging
. 2021 Jan 7;55(1):27–30. doi: 10.1007/s13139-020-00676-1

The Influence of H2-Receptor Antagonist Administration to the 24-h Uptake of I-131 in the Thyroid Gland

Andreas Lim 1,2,✉, Hendra Budiawan 2, A Hussein S Kartamihardja 1,2
PMCID: PMC7881069  PMID: 33643486

Abstract

Purpose

The aim of this study was to determine the influence of H2RAs to the 24-h I-131 uptake in the thyroid gland.

Material and Methods

A prospective study with quasi-experimental pre- and post-study design was done. Subjects with normal fT4 level who fulfilled the inclusion criteria were selected. All subjects received 0.2 mCi of I-131 orally, and the thyroid uptake calculations were performed at 24 h later. The same procedure was performed 4 weeks later. All of the subjects were asked to consume H2RAs 1 h before the administration of I-131 of the second procedure. Both 24-h thyroid uptakes were statistically analysed.

Results

A total of 14 subjects were enrolled in this study. Most of them were women (78%) with an average age of 37.6 years old (range: 20–55). This study showed a median of 24-h thyroid uptake of I-131 before and after H2-receptor antagonist of 20.6% (range: 11.1–57.8%) and 16.7% (range: 8.1–39.4%) respectively.

Conclusion

H2-receptor antagonist caused a significance reduction of 24-h I-131 uptake value in the thyroid gland.

Keywords: H2-receptor antagonist, Radioactive iodine, Thyroid gland 24-h uptake

Introduction

Hyperthyroidism and thyroid carcinoma are quite common diseases in the world. In Indonesia, the prevalence of hyperthyroidism is 6.9% [1], and thyroid carcinoma is the 11th most prevalent carcinoma with 11.470 new cases in 2018 [2]. Radioactive iodine (I-131) has been used widely in the management of patients with hyperthyroidism as well as thyroid carcinoma since the 1940s [3]. I-131 will enter the systemic circulation after being absorbed at the intestine following oral administration. I-131 will then be taken up by the thyroid gland and other organs with natrium-iodide symporter (NIS) expression [4, 5]. There are several factors that could alter the 24-h I-131 uptake in the thyroid gland, such as excess consumption of iodine from medication or diet, goitrogenic foods, thiourylene derivatives, aromatic antithyroid drugs, sedatives and hormones. All of that could cause lower 24-h I-131 thyroid uptake, while iodine deficiency condition could cause higher 24-h I-131 thyroid uptake [6]. H2-receptor antagonists (H2RAs) are a medication that has often been given before administration of I-131 to prevent the side effect of I-131, such as acute gastritis [7]. A study showed that H2RAs prolonged the gastric emptying time that could cause alteration of the I-131 biodistribution [8, 9]. To our knowledge, there are no other studies conducted to evaluate the influence of H2RAs to the I-131 thyroid uptake in humans. The aim of this study was to determine the influence of H2RAs to the 24-h I-131 uptake in the thyroid gland.

Material and Methods

Subject

A total of 14 voluntary subjects, between July 2019 and November 2019, with normal fT4 level were included in this study (Table 1). Subjects with gastropathy were excluded from this study. Expecting mother, lactating mother, having smoking habits or consumed medication that could alter the uptake of I-131 in thyroid gland, gastric physiology and/or H2RA bioavailability was also excluded.

Table 1.

Subjects characteristics and results

No. Sex Age (years) fT4 (ng/dL) 24-h I-131 uptake in thyroid gland pre-intervention (%) 24-h I-131 uptake in thyroid gland post-intervention (%)
1 F 48 1.1 21.1 17.3
2 F 24 1.2 18.5 16.1
3 F 34 1.3 20.1 15.1
4 M 33 1.8 49.4 39.4
5 M 28 1.4 20.1 17.7
6 F 43 0.8 33.3 14.9
7 F 39 1.0 35.3 22.7
8 F 53 1.1 57.8 31.1
9 F 55 1.2 30.6 24.2
10 F 44 1.1 15.7 14.6
11 F 35 1.2 11.1 8.1
12 F 37 1.5 18.0 16.0
13 M 34 1.6 16.8 12.8
14 F 20 1.4 29.0 20.2

H2-Receptor Antagonist Administration

H2-receptor antagonists were given orally 1 h before the I-131 for the second procedure was administered. Ranitidine 150 mg was the chosen H2RA. It was given twice daily, with a total of 450 mg Ranitidine consumed by each subject, until the day the second procedure was performed.

Thyroid Uptake Calculation

Baseline uptake calculations of the thyroid gland were performed before consuming ranitidine. The uptake calculation was performed at 24 h after administration of 0.2 mCi of I-131 for both procedures, before and after ranitidine administration. The interval between both procedures was 4 weeks. The uptake calculation was performed using a Siemens® SPECT/CT camera with high-energy general-purpose collimator for 10 min. Region of interest was drawn covering all the thyroid gland, and then region of interest of the background was drawn below it.

The 24-h I-131 uptake was calculated using the following formula [10]:

uptake=Pthyroid−P_backgroundPrecount−Postcount

where P_thyroid is thedecay-corrected total thyroid counts, P_backgroundis the decay-corrected background counts, Precountis the decay-corrected counts of the pre-injection syringe image and Postcountis the decay-corrected counts of the post-injection syringe image.

Decay correction is calculated by multiplying the image counts by the factor:

exp=−0.693t/T1/2

where t is the time that elapses between preparation of the radiopharmaceutical and image acquisition and T1/2 is the half-life time of the tracer.

A standard syringe was used to determine the exact t value.

Statistical Analysis

Shapiro-Wilk test was used to analyse the distribution of the data. Then Wilcoxon test was used to analyse the significance of the differences. The Statistical Product and Service Solutions (SPSS) v.15 software was used to analyse these data, with p value < 0.05 considered to be significant.

Result

A total of 14 subjects (3 males and 11 females) were included in this study with an average age of 37.6 years old (range: 20–55). The average fT4 level of 1.26 ng/dL with normal value of 0.8–1.8 ng/dL (Table 1).

There was a significant difference of the 24-h I-131 uptake in the thyroid gland between pre- and post-H2RA administration (p < 0.05). Baseline uptake calculation showed a median of 20.6% 24-h I-131 uptake value in the thyroid gland; while on the second uptake calculation, after ranitidine consumption, it showed a median of 16.7% (Table 2).

Table 2.

Comparison of the 24-h I-131 uptake in thyroid gland pre- and post-H2RA administration

24-h I-131 uptake in the thyroid gland Measurement p value*
Pre-H2RA administration Post-H2RA administration
Median 20.6 16.7 < 0.001
Range 11.1–57.8 8.1–39.4

*Wilcoxon test

This study also showed a median of 4.5% (1.1–26.7%) reduction in the 24-h I-131 uptake value in thyroid gland in the second procedure (Table 3). The median was chosen in this study due to the abnormality of data distribution (based on Shapiro-Wilk test).

Table 3.

24-h I-131 uptake reduction in thyroid gland post-H2RA administration

Median Range
24-h I-131 uptake reduction in thyroid gland 4.5 1.1–26.7
Percentage of 24-h I-131 uptake reduction in thyroid gland 22.4 7.0–55.3

Discussion

Radionuclide therapy has been conducted since the discovery of radioactivity by Henri Becquerel and Marie Curie in the 1900s [11]. Radioactive iodine (I-131) was found by Glenn Seaborg and John Livingood in 1938; however, it has not been used to treat thyroid carcinoma until August 1946 [12]. I-131 can also be used to treat benign thyroid disorders, such as Graves’ diseases, toxic nodular goitre and autonomous thyroid nodule [3, 13].

Orally administered I-131 will be accumulated in the gaster and will be emptied into the intestine where it will be absorbed to enter the systemic circulation before taken up by organs with natrium-iodine symporter (NIS) expression [4, 5].

I-131 can cause damage to gastric mucosa that can manifest as acute gastritis [14]. Therefore, a premedication, whether H2-receptor antagonist or proton pump inhibitor, is usually given before administrating the I-131 [7]. H2-receptor antagonist suppresses the production of gastric acid, which can affect the motility of the stomach and prolong the gastric emptying time [8, 15–17].

This study showed a significant difference of 24-h I-131 uptake between pre- and post-H2RA administration with median reduction of 22.4% (p < 0.001). It was probably due to the effect of H2RAs that suppressed the production of gastric acid and prolong that the gastric emptying time. In this case, I-131 needed longer time to reach and absorbed in the intestine. This phenomenon caused the reduced of 24-h I-131 uptake value in thyroid gland. However, a further study is necessary to be done to determine the effect of H2RA premedication to the efficacy of I-131 therapy.

Conclusion

This study showed that H2-receptor antagonist caused a significant reduction towards 24-h I-131 uptake value in the thyroid gland. This effect of H2RA premedication should be considered in determining the dose of I-131 for the treatment of thyroid disease.

Limitation

This study has several limitations, such as the number of the study subjects was small, and we did not evaluate the fT4 level after the procedures.

Compliance with Ethical Standards

Conflict of Interest

Andreas Lim, Hendra Budiawan and Achmad Hussein Sundawa Kartamihardja declare that they have no conflict of interest.

Ethical Approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of Dr. Hasan Sadikin General Hospital Bandung and had been approved by the Ethical Committee (Number: LB.02.01/X.6.5/195/2019).

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Andreas Lim, Email: andreaslim2712@gmail.com.

Hendra Budiawan, Email: dvn_b@yahoo.com.

A. Hussein S. Kartamihardja, Email: husseinsundawa@yahoo.com

References

  • 1.Task Force on Thyroid Disease TIS of E Indonesian clinical practice guidelines for hyperthyroidism. J ASEAN Fed Endocr Soc. 2014;27:34. [Google Scholar]
  • 2.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 3.Mettler FA. Essentials of nuclear medicine. 6. Philadelphia: Elsevier Saunders; 2012. [Google Scholar]
  • 4.Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–1200. [PubMed] [Google Scholar]
  • 5.Johansson L, Leide-Syegborn S, Mattsson S, Nosslin B. Biokinetics of iodine in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm. 2003;18:445–450. doi: 10.1089/108497803322285206. [DOI] [PubMed] [Google Scholar]
  • 6.Grayson RR. Factors which influence the radioactive iodine thyroidal uptake test. Am J. 1960;28:397–415. doi: 10.1016/0002-9343(60)90171-6. [DOI] [PubMed] [Google Scholar]
  • 7.Elisei R, Agate L, Mazzarri S, Bottici V, Guidoccio F, Molinaro E, et al. Diagnostic application of nuclear medicine: thyroid tumors. In: Strauss HW, Mariani G, Volterrani D, Larson SM, et al., editors. Nuclear oncology: from pathophysiology to clinical applications. 2. Switzerland: Springer International; 2017. pp. 545–583. [Google Scholar]
  • 8.Takashi N, Takaomi K, Yuji O, Kento I, Shogo Y, Tadahiko S, et al. Effects of histamine-2 receptor antagonist and proton pump inhibitors on the rate of gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system) J Neurogastroenterol Motil. 2011;17:287–293. doi: 10.5056/jnm.2011.17.3.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Edwards O, Yakish ED, CNMT. Wang L-M, Wu Q, Hoffman JM, Morton KA. Histamine receptor 1 and 2 antagonist alter biodistribution of radioiodine. J Nucl Med Technol. 2015;43:214–219. doi: 10.2967/jnmt.115.160697. [DOI] [PubMed] [Google Scholar]
  • 10.Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, Royal H, Sarkar S. Procedure guideline for thyroid uptake measurement: 1.0. J Nucl Med. 1996;37:1266–1268. [PubMed] [Google Scholar]
  • 11.Yeong C-H, Cheng M-H, Ng K-H. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B. 2014;15:845–863. doi: 10.1631/jzus.B1400131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Means JH. Historical background of the use of radioactive iodine in medicine. N Engl J Med. 1955;252:936–940. doi: 10.1056/NEJM195506022522204. [DOI] [PubMed] [Google Scholar]
  • 13.Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNM practice guideline for therapy of thyroid disease with 131I 3.0*. J Nucl Med. 2012;53:1–19. doi: 10.2967/jnumed.112.105148. [DOI] [PubMed] [Google Scholar]
  • 14.Sezer A, Celik M, Usta U, Altun GD. Gastric damage related to radioactive iodine treatment and protective effect of amifostine. Biomed Res. 2017;28:3705–3710. [Google Scholar]
  • 15.Corinaldesi R, Scarpignato C, Galassi A, Stanghellini V, Calamelli R, Bertaccini G, Barbara L. Effect of ranitidine and cimetidine on gastric emptying of a mixed meal in man. Int J Clin Pharmacol Ther Toxicol. 1984;22:498–501. [PubMed] [Google Scholar]
  • 16.Forrest JA, Heading RC, Park J, Carter DC, Lennon J, Lidgard G, Shearman DJ. Effect of histamine H2-receptor blockade on gastric emptying and serum gastrin in man. Scott Med J. 1976;21:23–27. doi: 10.1177/003693307602100107. [DOI] [PubMed] [Google Scholar]
  • 17.Bertaccini G, Coruzzi G. Cholinergic-like effects of the new histamine H2-receptor antagonist ranitidine. Agents Actions. 1982;12:168–171. doi: 10.1007/BF01965134. [DOI] [PubMed] [Google Scholar]

Articles from Nuclear Medicine and Molecular Imaging are provided here courtesy of Springer

RESOURCES